Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.60 |
| ▸ | PLK1 | P53350 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ICMT | O60725 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379289 | 0.91 | CDC25A (0.68) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL10965765 | 0.88 | ICMT (0.71) | CDC25AMCL1ICMTHTR6 | |
| SCHEMBL29376139 | 0.86 | CDC25A (0.67) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL15747715 | 0.86 | CDC25A (0.80) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL28840792 | 0.85 | CDC25A (0.73) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL28370235 | 0.85 | CDC25A (0.73) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL18180209 | 0.84 | CDC25A (0.63) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL15747729 | 0.84 | CDC25A (0.90) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL2945684 | 0.83 | CDC25A (0.63) | CDC25AMCL1PLK1ALDH1A1LMNA | |
| SCHEMBL3743075 | 0.83 | CDC25A (0.70) | CDC25AMCL1PLK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481587-B2 | Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-07-09 | — | — | US | disclosed |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | IDO1, TPH1, FOXM1 | CDC25A 691/4885MCL1 1202/4885PLK1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.